Applying reflective multicriteria decision analysis to understand the value of therapeutic alternatives in the management of gestational and peripartum anaemia in Spain

• Published in: BMC pregnancy and childbirth Vol. 22; no. 1; p. 157
• Main Authors: Casellas Caro, Manel, Hidalgo, María Jesús Cancelo, García-Erce, José Antonio, Baquero Úbeda, José Luis, Torras Boatella, Maria Glòria, Gredilla Díaz, Elena, Ruano Encinar, Margarita, Martín Bayón, Israel, Nicolás Picó, Jordi, Arjona Berral, José Eduardo, Muñoz Solano, Alberto, Jiménez Merino, Silvia, Cerezales, Mónica, Cuervo, Jesús
• Format: Journal Article
• Language: English
• Published: England BioMed Central 25.02.2022; BMC
• Subjects: Anemia; Anemia, Iron-Deficiency - drug therapy; Clinical decision-making; Decision Support Techniques; Female; Ferric carboxymaltose; Ferric Compounds - therapeutic use; Ferrous Compounds - therapeutic use; Humans; Maltose - analogs & derivatives; Maltose - therapeutic use; Pregnancy; Pregnancy Complications, Hematologic - drug therapy; Risk Assessment; Shared decision making; Spain - epidemiology; Stakeholder Participation; Technology assessment; Spain; Pregnancy; Shared decision making; Anemia; Clinical decision-making; Ferric carboxymaltose; Technology assessment
• ISSN: 1471-2393; 1471-2393
• DOI: 10.1186/s12884-022-04481-w

The objective of the FeminFER project was to assess the value of ferric carboxymaltose following a multicriteria decision analysis in obstetrics and gynaecology in Spain. Ferric carboxymaltose (FCM) and ferrous sulphate were evaluated using the EVIDEM framework. Ten stakeholders participated to collect different perspectives. The framework was adapted considering evidence retrieved with a PICO-S search strategy and grey literature. Criteria/subcriteria were weighted by level of relevance and an evidence-based decision-making exercise was developed in each criterion; weights and scores were combined to obtain the value of intervention relative to each criterion/subcriterion, that were further combined into the Modulated Relative Benefit-Risk Balance (MRBRB). The most important criterion favouring FCM was Compared Efficacy/Effectiveness (0.183 ± 0.07), followed by Patient Preferences (0.059 ± 0.10). Only Direct medical costs criterion favoured FS (-0.003 ± 0.03). MRBRB favoured FCM; 0.45 ± 0.19; in a scale from -1 to + 1. In conclusion, considering the several criteria involved in the decision-making process, participants agreed with the use of FCM according to its MRBRB.